Trial Profile
A Pilot Study of Neoadjuvant Monoclonal Antibody Humanised (hu) J591 for the Treatment of High and/or Intermediate-Risk Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ATL 101 Telix Pharmaceuticals (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Oct 2020 Status changed from active, no longer recruiting to completed.
- 05 Sep 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2022.
- 28 Feb 2018 Status changed from recruiting to active, no longer recruiting.